title: Primary gastric mucosa associated lymphoid tissue lymphoma: clinical data predicted treatment outcome.
abstract: OBJECTIVE
  To determine clinical characteristics and treatment outcome of gastric lymphoma after chemotherapy and immuno-chemotherapy.
  
  
  METHODS
  Thirty four patients with primary gastric mucosa associated lymphoid tissue (MALT) lymphoma (Ann Arbor stages I to IV) were enrolled. All had upper gastric endoscopy, abdominal ultrasonography, CT and H pylori status assessment (histology and serology). After anti-H pylori treatment and initial chemotherapy, patients were re-examined every 4 mo.
  
  
  RESULTS
  Histological regression of the lymphoma was complete in 22/34 (64.7%) and partial in 9 (26.5%) patients. Median follow up time for these 31 responders was 60 mo (range 48-120). No regression was noted in 3 patients. Among the 25 (73.5%) H pylori positive patients, the eradication rate was 100%.
  
  
  CONCLUSIONS
  Using univariate analysis, predictive factors for overall survival were international prognostic index (IPI) score, hemoglobin level, erythrocyte sedimentation rate (ESR), and platelet numbers (P < 0.005). In addition to this, Cox proportion hazard model differentiate IPI score, ESR, and platelets as predictors of survival.
authors.affiliation: Institute of Hematology, Clinical Center of Serbia, Belgrade, Serbia. bb.lena@gmail.com
authors.forename: Milena
authors.initials: M
authors.lastname: Todorovic
authors.forename: Bela
authors.initials: B
authors.lastname: Balint
authors.forename: Miodrag
authors.initials: M
authors.lastname: Jevtic
authors.forename: Nada
authors.initials: N
authors.lastname: Suvajdzic
authors.forename: Amela
authors.initials: A
authors.lastname: Ceric
authors.forename: Dragana
authors.initials: D
authors.lastname: Stamatovic
authors.forename: Olivera
authors.initials: O
authors.lastname: Markovic
authors.forename: Maja
authors.initials: M
authors.lastname: Perunicic
authors.forename: Slobodan
authors.initials: S
authors.lastname: Marjanovic
authors.forename: Miodrag
authors.initials: M
authors.lastname: Krstic
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001799:Blood Sedimentation; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D053208:Kaplan-Meier Estimate; D018442:Lymphoma, B-Cell, Marginal Zone / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D010976:Platelet Count; D016016:Proportional Hazards Models; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D006454:Hemoglobins